METTL1 and osteosarcoma: METTL1 decreases FTH 1 expression by enhancing m7G modification of FTH 1 and pri-miR-26a, and thus increase ferroptosis, thereby reducing chemoresistance of osteosarcoma, so targeted therapy on METTL1 may be a potential and promising treatment strategy for osteosarcoma [111].